Trial Profile

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Biomarker; Pharmacogenomic; Therapeutic Use
Acronyms PHOENIX

11 Aug 2025 Planned number of patients changed from 81 to 119.
11 Aug 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2029.
11 Aug 2025 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com